SUPRIYA

SUPRIYA

Pharmaceuticals & Drugs

344.15

0.00 (0.00%)

stock change
Market Cap2,823 CrEPS15.0High354.7
Stock P/E23.4Net Profit Margin21.3Low346.45
home icon
The current prices are delayed, login to your account to see live prices.
LOGIN
explain

Performance

Today’s Low

Today’s High

346.45

354.7

52W Low

52W High

170.15

394

Open Price347.2Volume481
Prev. Close347.2
explain

Fundamentals

explain
Market Cap2,823 CrROE13.7%
P/E Ratio(TTM)23.4EPS(TTM)0.0
P/B Ratio3.6Dividend Yield0.2%
Industry P/E43.7Book Value97.3
Face Value2.0
explain

About the Company

The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.

The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA.

Business area of the company

The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Awards, accreditations or recognitions

  • 2009: Certificate of Excellence for outstanding Export Performance in the product group Chemicals, Drugs, Pharma and Allied Products (MSME) awarded by Federation of Indian Export Organisations.
  • 2010: Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India.
  • 2016: Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra.
  • 2016: Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra.
  • 2017: Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
  • 2017: Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra.
  • 2019: Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India.

Major events and milestones

  • 2008 Incorporation of the Company upon its conversion from a partnership firm to a public limited company.
  • 2009: Started production of Ketamine Hydrochloride.
  • 2010: CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate.
  • 2011: IDL granted for Chlorphenamine Maleate.
  • 2013: COFEPRIS and KFDA approval granted.
  • 2014: USFDA approval granted
  • 2014: IDL granted for Brompheniramine Maleate.
  • 2015: EUGMP and EDQM approval granted.
  • 2017: CEP (Certificate of Sustainability) granted for Pheniramine Maleate.
  • 2017: Second time USFDA approval granted.
  • 2018: CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride.
  • 2020: Third time USFDA approval.
  • 2021: CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
  • 2021: NMPA approval granted.
  • 2021: Health Canada approval.
Parent OrganizationSupriya Lifescience Ltd.Managing DirectorSatish Waman Wagh
Founded2008NSE SymbolSUPRIYA
explain

Financials

All values are in Rs Cr

explain

Shareholding Pattern

Domestic Institutions

Foreign Institutions

Mutual Funds

Promoters

Domestic Institutions

Foreign Institutions

Mutual Funds

Promoters

Domestic Institutions

Foreign Institutions

Mutual Funds

Promoters

Domestic Institutions

Foreign Institutions

Mutual Funds

Promoters

Domestic Institutions

Foreign Institutions

Mutual Funds

Promoters

explain

Peer Comparison

Company52 WeekMarket PriceP/E RatioFinancialsShare Holding
344.15(-0.9%)
23.4
527.4(-0.2%)
44.9
99.1(0.8%)
10.6
49.2(0.0%)
34.1
explain

Recently Viewed

No Recently Viewed Stocks
explain

Frequently asked questions

You can buy the shares of Supriya Lifescience using the Trinkerr Website or by downloading the Trinkerr app from Android and Apptore.